Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
This lipid-based system is able to tightly target antigen-presenting cells and thus trigger a rapid, persistent and robust T cell response against various cancers.
The U.S. Food and Drug Administration granted Emergency Use Authorization (EUA) for the Pfizer-BioNTech vaccine for children ages 5 to 11.
A new study was published this week and proposed a potential new biomarker for predetermining patient responsiveness to immune checkpoint blockade therapy.
Albert Bourla, chief executive officer of Pfizer, argued this week that politicians were approaching the problem of drug pricing the wrong way — as usual.
Daiichi Sankyo announced the decision in its third quarter financial report this morning, where it said that the Phase I data yielded no clear responses in GIST patients.
The 174,000 square-foot location will house a fully-equipped production plant to create its initial programs for Type 1 diabetes, a specific genetic cause of autism, galactosemia, and more.
Gilead Sciences has one of the most robust HIV pipelines in the world. New real-world data from the ongoing BICSTaR study demonstrates benefits of HIV drug Biktarvy.
Yet another busy week for clinical trial news. Here’s a look.
After first reporting that its investigational RNAi drug vutrisiran hit its 9-month Phase III endpoints, Alnylam announced it continues to demonstrate positive results at the 18-month mark.
In the face of Delta, the actual efficacy of the vaccines has come into question, while global cases and deaths from COVID-19 increased for the first time in two months, primarily in Europe.
Kymera was able to demonstrate for the first time proof-of-biology ex vivo using whole blood from one of their KT-474 treated patient cohorts.
The life sciences industry continues to be one of the fastest growing industries in the world as the end of the year draws near.